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Over the same period, we detected EGFR mutations in 45.6% of adenocarcinoma (AD) patients (327/717) who had specified EGFR gene mutation status. Therefore, the EGFR mutation rate in ADSQCC was approximately half that in AD. Additional analysis showed that relapse-free survival and overall survival in ADSQCC patients with higher ratios of AD components did not significantly differ from those with lower ratios.
As Dr. Satoh mentions, examining whether both cell types of ADSQCC harbored the identical mutation would confer not only clinical importance but also biological interest in non-small cell lung cancers. Unfortunately, as we did not perform microdissection procedures during DNA extraction from these tissue samples, separate evaluation of gene status between the AD and squamous cell carcinoma (SQCC) components was not possible.
Nonetheless, we suspect that the two histologic components in ADSQCC might be morphological alterations from a genetically monoclonal origin. A recent investigation provided further profound evidence to support a monoclonal origin for this tumor. 2 Furthermore, EGFR mutations have been observed in a certain percentage of SQCC lung cancers, 3 which supports the validity of EGFR mutations in SQCC.
These findings suggest a possibility that mutated EGFR acts as a driver oncogene in the tumor initiation period, and then morphological changes to adenocarcinoma or SQCC develop in the tumor promotion period. As shown in Fig. 3 of our article, 1 the finding that EGFR mutations were widely dispersed in ADSQCC tumors irrespective of the proportion of adenocarcinoma also supports this possibility.
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